

Nexviazyme™ (avalglucosidase alfa-ngpt) Injection



Pharmacy Coverage Policy

Effective Date: October 20, 2021

Revision Date: September 27, 2023

Review Date: September 20, 2023

Line of Business: Medicare, Commercial, Medicaid - South Carolina, Medicaid - Ohio

Policy Type: Prior Authorization

Page: 1 of 2

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to date version. Refer to http://apps.humana.com/tad/tad_new/home.aspx to verify that this is the current version before utilizing.

Products Affected

Nexviazyme intravenous solution

Listed Indications

[Late-Onset Pompe Disease](#)

Late-Onset Pompe Disease

Does the member meet all of the following criteria?

Criteria #1	The member has a diagnosis of late-onset Pompe Disease
Criteria #2	The diagnosis is supported by lab and/or genetic testing consistent with late-onset Pompe disease (e.g. evidence of GAA enzyme deficiency, identification of pathogenic variants in GAA gene)

Approval Duration

Initial	plan year duration
---------	--------------------

[Back to top](#)

Background

This is a prior authorization policy about Nexviazyme (avalglucosidase-alfa).

Pompe is a type of glycogen storage disease, meaning patients have an excessive build-up of a complex sugar molecule known as glycogen within their cells, especially in muscle cells. This is because of a defect in the GAA gene that causes low levels of the acid alpha-glucosidase enzyme to be produced, an enzyme that is crucial in breaking glycogen down into glucose. Different types of mutations in the GAA gene can affect how much of a functional acid alpha-glucosidase enzyme exists in cells. The type and severity of Pompe disease depends on the levels of the working acid alpha-glucosidase enzyme. Symptom onset in late-onset Pompe disease can occur anytime after the age of 1 year. People with late-onset Pompe have higher GAA enzyme levels than are found in the infantile-onset forms of this disease, but generally less than 40 percent of "normal" levels. In comparison, infantile-onset Pompe patients typically have less than 1 percent of GAA enzyme activity, while those with non-classic forms usually have less than 10 percent. The actual frequency of late-onset Pompe disease in the U.S. is unknown but it is estimated to be as high as 1 in 40,000.

Black Box Warnings:

- Hypersensitivity reactions, including anaphylaxis: appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, therapy should be discontinued immediately and appropriate medical treatment should be initiated
- Infusion-associated reactions (IARs): If severe IARs occur, consider immediate discontinuation and initiation of appropriate medical treatment
- Risk of Acute Cardiorespiratory Failure in susceptible patients: Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function, may be at risk of serious exacerbation of their cardiac or respiratory status during the infusion

Nexviazyme (avalglucosidase-alfa) is an enzyme replacement therapy.

Avalglucosidase alfa is the lysosomal enzyme acid alpha-glucosidase (GAA). The GAA enzyme is required for lysosomal glycogen degradation. Once it binds to the mannose 6-phosphate receptor, it is transported into the lysosome where it can ultimately cleave the glycogen inside. This results in a

Nexvazyme™ (avalglucosidase alfa-ngpt) Injection

Effective Date: 10/20/2021

Revision Date: 9/27/2023

Review Date: 9/20/2023

Line of Business: Medicare, Commercial, Medicaid - South Carolina, Medicaid - Ohio

Policy Type: Prior Authorization

Page: 2 of 2

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to date version. Refer to http://apps.humana.com/tad/tad_new/home.aspx to verify that this is the current version before utilizing.

decrease accumulation of the lysosomal glycogen in the skeletal and heart muscles, potentially resulting in decrease in muscular weakness and/or respiratory and heart failure.

Nexvazyme (avalglucosidase-alfa) is indicated for the treatment of patients aged 1 year and older with late-onset Pompe disease (GAA deficiency)

Avalglucosidase alfa is available as brand Nexvazyme in a 100 mg single use vial

Provider Claim Codes

For medically billed requests, please visit www.humana.com/PAL. Select applicable Preauthorization and Notification List(s) for medical and procedural coding information.

Medical Terms

Nexvazyme; avalglucosidase alfa-ngpt; Pharmacy; Late-onset Pompe disease; Orphan; intravenous

References

1. Barba-romera, MA, Barrot E, Bautista-lorite J, et al. Clinical guidelines for late-onset Pompe disease. *Rev Neurol* 2012; 54 (8): 497-507
2. Clinical Pharmacology [database online]. Tampa, FL; Gold Standard, Inc. Updated periodically. <https://www.clinicalkey.com/pharmacology>
3. Culper EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. *Muscle Nerve* 2021; 45: 319–333
4. DRUGDEX® System [Internet database]. Greenwood Village, Colo: Thompson Reuters (Healthcare) Inc. Updated periodically.
5. Nexvazyme [prescribing information]. Genzyme Corporation. April 2023.
6. Pompe Disease: Rare Disease Database; NORD: National Organization for Rare Disorders. 2020. <https://rarediseases.org/rare-diseases/pompe-disease>

Disclaimer

State and federal law, as well as contract language, including definitions and specific inclusions/exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage. Coverage may also differ for our Medicare and/or Medicaid members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determinations (NCD), Local Medical Review Policies (LMRP) and/or Local Coverage Determinations. See the CMS website at <http://www.cms.hhs.gov/>. The member's health plan benefits in effect on the date services are rendered must be used. Clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise without permission from Humana.